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Immunoglobulin (Ig) replacement therapy dramatically changed the clinical course of pri-
mary hypogammaglobulinemias, significantly reducing the incidence of infectious events.
Over the last two decades its use has been extended to secondary antibody deficien-
cies, particularly those related to hematological disorders as lymphoproliferative diseases
(LPDs) and multiple myeloma. In these malignancies, hypogammaglobulinemia can be
an intrinsic aspect of the disease or follow chemo-immunotherapy regimens, including
anti-CD20 treatment. Other than in LPDs the broadening use of immunotherapy (e.g.,
rituximab) and immune-suppressive therapy (steroids, sulfasalazine, and mycophenolate
mofetil) has extended the occurrence of iatrogenic hypogammaglobulinemia. In particular,
in both autoimmune diseases and solid organ transplantation Ig replacement therapy has
been shown to reduce the rate of infectious events. Here, we review the existing liter-
ature about Ig replacement therapy in secondary hypogammaglobulinemia, with special
regard for subcutaneous administration route, a safe, effective, and well-tolerated treat-
ment approach, currently well established in primary immunodeficiencies and secondary
hypogammaglobulinemias.
Keywords: immunoglobulin replacement therapy, secondary hypogammaglobulinemia, chronic lymphocytic
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INTRODUCTION
Immunoglobulins (Ig) have been commercially available since the
1940s, and first carried out as replacement therapy (IgRT) in
a patient with agammaglobulinemia in 1951 by Ogden Bruton.
From that first experience on, Ig have been widely used in patients
with primary immune deficiency (PID), as it is well known that
hypogammaglobulinemia is a crucial risk factor for development
of infectious events and IgRT is able to reduce this risk. By contrast,
the lack of clear indications regarding the use of prophylactic IVIG
in secondary antibody deficiencies (SAD) may appear paradoxical,
if we consider the broad range of disorders in which hypogamma-
globulinemia is an intrinsic aspect of the disease or a iatrogenic
consequence (Table 1) and being the number of affected patients
significantly higher than in PID.
In this review, we summarize the most common conditions in
which SAD can be observed. We also describe evidence indicating
the possibility of subcutaneous (SCIG) rather than intravenous
(IVIG) Ig for the treatment for SAD.
CHRONIC LYMPHOCYTIC LEUKEMIA
Infective complications account for up to 50% of all chronic
lymphocytic leukemia (CLL)-related deaths (1). Their etiology
is multifactorial, due to disease-related immune defects and/or
chemo-immunotherapy treatment regimens (2, 3). Hypogamma-
globulinemia is the most common chronic immune defect in
patients with CLL (the prevalence ranges from 20 to 70%), and
correlates with duration and stage of the disease (4). The defect
is usually irreversible even in patients achieving complete disease
remission. A direct relationship was found between low levels of
IgG and the frequency/severity of infections.
Two main strategies are indicated in UK guidelines for patients
with hypogammaglobulinemia who develop recurrent bacter-
ial infections (1): antibiotic prophylaxis and IgRT. Nonetheless,
there are no standard guidelines for antimicrobial prophylaxis in
CLL patients, and most recommendations are derived from small
clinical trials and anecdotal reports (4, 5).
Regarding prophylactic IVIG in patients with CLL and
hypogammaglobulinemia, randomized controlled studies have
been performed in the 1980s ad 1990s and recently summarized
(6): they suggest that the use of IVIG may be considered in patients
with hypogammaglobulinemia secondary to CLL who experience
recurrent infections, since IVIG could significantly decrease the
number of infections and the use of antibiotics, reducing hospital-
ization need and loss of working days. Despite this, the authors did
not found any difference in all cause mortality between the treated
and control group, maybe due to the relatively short follow-up
time (1 year). For these reasons, according to UK guidelines IgRT
indicated in patients with a serum IgG< 500 mg/dl complaining
of recurrent or severe infections (1). Similar indications are sug-
gested in the Canadian guidelines (7) and by the panel group of the
Primary Immunodeficiency Committee of the American Academy
of Allergy,Asthma, and Immunology (8). In all these guidelines, an
initial dose of 400 mg/kg administered intravenously 3–4 weekly
is suggested, aiming at a trough level of 600–800 mg/dl (1, 7). The
Ig dose should be then adjusted according to clinical response
and steady state trough levels (IgG trough level> 400 mg/dl). As
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in PID, higher trough levels may be beneficial in patients with
underlying co-morbidities, particularly bronchiectasis. On the
basis of these evidences and our experience (9), the same indi-
cations are followed in our outpatient clinic. We regularly evaluate
the response to IgRT after 12 months, to assess its efficacy and to
judge the need of continuing or stopping the infusions.
Attempts have been made to define the risk factors for infec-
tions in CLL, in order to select patients who could benefit from
IgRT even with a pre-emptive approach. In two papers (10, 11),
factors other than Ig concentration (previous chemotherapy, clini-
cal stage, CD38 expression, genetic analysis, and IgVH mutations)
have been pointed out as the main prognostic markers for the
development of infections, while low IgG level seem not to be
clearly associated with infections. Nonetheless, in these studies
IgG levels were recorded independently from infectious events, at
diagnosis or at the moment of the survey. In CLL, hypogamma-
globulinemia is commonly progressive over time; thus, IgG levels
evaluated at onset of the disease may significantly differ from
levels observed at the time of infection onset. Dhalla et al. (12)
suggested that immunization responses could be used to stratify
infection risk and select patients for IgRT, but caution is recom-
mend since interpreting immunization assays is complex, cut-off
levels may vary and there are controversies in stating what consti-
tutes an adequate response. Finally, Freeman et al. (13) suggested
that screening patients with CLL for IgG subclass deficiency may
be a useful adjunct in stratifying their risk for infection, since
they were able to show a significant relationship between any IgG
subclass deficiency and infections, regardless of the total Ig level.
MULTIPLE MYELOMA
Infection is a significant cause of morbidity and the leading cause
of death in patients with multiple myeloma (MM) (14). The
increased susceptibility to infections results from the interplay
between antineoplastic therapies and disease-related complica-
tions (15). Moreover, novel treatments significantly prolonged
survival transforming MM into a chronic condition, character-
ized by multiple relapses and salvage therapies, resulting in an
increased cumulative immunosuppression and a higher risk for
infection. The incidence of infectious events varies in different
phases of MM (16), and seems to be higher during active disease
and in the first months of induction chemotherapy. In early-stage
MM, the most common infections involve the respiratory tract,
manifesting as bronchitis and pneumonia. These infections are
Table 1 | Main causes of secondary hypogammaglobulinemia.
Secondary hypogammaglobulinemia
Excessive loss of immunoglobulins Protein-losing enteropathy
Nephrotic syndrome
Severe burns
Malignancy Chronic lymphocytic leukemia
Multiple myeloma
Good’s syndrome
Non-Hodgkin B cell lymphomas
Drug induced SeeTable 2
predominantly caused by H. influenzae or S. pneumonia, suggest-
ing a role of hypogammaglobulinemia in their pathogenesis. In
patients with advanced disease and during the neutropenic phases
of intensive chemotherapy, S. aureus and gram-negative bacteria
are more common, thus implying different underlying pathogenic
mechanisms.
As in CLL, only few studies evaluated the role of IgRT in patients
with hypogammaglobulinemia and MM. Chapel et al. (17) in 1994
performed a randomized, double-blind, placebo-controlled, mul-
ticenter trial of IVIG employed as prophylaxis against infection in
82 patients with stable MM; the authors demonstrated a protective
role of IVIG against life-threatening infections and a significant
role in reducing the risk of recurrent infections. Other two studies
have been performed in patients with hypogammaglobulinemia
and either CLL or MM, obtaining similar results (6). Conversely,
Blombery et al. (18) showed no benefit of the use of peritrans-
plant IVIG to reduce infectious complications in hypogamma-
globulinemic patients with MM undergoing autologous stem cell
transplantation.
In our opinion, regular Ig substitution should be considered in
MM patients who suffer from life-threatening or recurrent infec-
tions that are reasonably thought to be caused by low levels of
polyclonal Ig (16, 19). Similar indications are suggested in the
Canadian guidelines about IgRT (7), where the proposed regimen
consists of 400 mg/kg of IVIG administered every 4 weeks, sub-
sequently adjusted to reach an individualized “biological” trough
level. Prophylactic therapy with Ig during autologous stem cell
transplantation is not recommended. Unfortunately, we observed
that it may be not so easy to exactly define the level of polyclonal Ig
in patients with MM, due to the presence of the monoclonal pro-
tein that interfere with Ig determinations. We suggest that clinical
evaluation and anamnestic aspects are fundamental to decide if
may be helpful to prescribe or not substitutive therapy in MM.
IATROGENIC HYPOGAMMAGLOBULINEMIA
As shown in Table 2, pharmacological history of the patient should
be carefully evaluated when hypogammaglobulinemia is detected.
One of the most used drug able to induce iatrogenic
hypogammaglobulinemia is the anti-CD20 monoclonal antibody
Table 2 | Main causes of drug-induced hypogammaglobulinemia.
Drug-induced hypogammaglobulinemia
Anti B cells monoclonal antibodies Rituximab
Belimumab
Immunosuppressants and chemotherapeutics Steroids
Gold salts
Azathioprine
TKI inhibitors Imatinib
Dasatinib
Anticonvulsants Carbamazepine
Valproate
Others (sporadically described) Ramipril
Acetylsalicylic acid
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rituximab. Firstly experimented and introduced in the clinical
practice for the treatment of hematological malignancies, it has
become a commonly used immune modulatory strategy for the
treatment of many refractory or poorly controlled autoimmune or
inflammatory disorders. Removal of CD20-expressing cell popu-
lations induces a dysregulation of immune homeostasis, impacting
regulatory functions of normal B cells (20, 21). Hypogamma-
globulinemia represents common negative consequences of this
imbalance (22–27), and is considered the main factor that influ-
ences the increased risk of infection in patients receiving rituximab
(28–30). According to recent hypotheses (31–33), a subgroup of
rituximab-induced hypogammaglobulinemias should be consid-
ered as the consequence of the presence of a latent PID. In some
cases, rituximab would elicit the antibody defect in genetically
predisposed individuals (34).
Kelesidis et al. (35) recently summarized the available evidence
about rituximab use and infections: the risk was increased in
patients with hematological malignancies, while in patients with
autoimmune diseases the risk was similar to other treatments.
However, considering the number of confounders potentially
masking or modulating the overall effects (e.g., co-morbidities,
concurrent chemotherapy, presence of neutropenia, number of
rituximab cycles, etc.), caution has been suggested in drawing
definitive conclusions. In hematological conditions, the incidence
of transient or persistent hypogammaglobulinemia following
rituximab-therapy ranges from 15 to 40% (28). Female gender,
fludarabine association regimens (36), and administration after
autologous stem cell transplantation (37–40) have been identi-
fied as main risks factors, while maintenance therapy for follicular
lymphoma is associated with a very low incidence of hypogamma-
globulinemia (41). Regarding autoimmune disorders, two recent
studies described a possible detrimental effects of rituximab on
Ig synthesis in patients with ANCA-associated vasculitides (42,
43), and in particular in patients relapsing after cyclophosphamide
treatment (43). Conversely, other studies contradict these obser-
vations: Marco et al. (44) reported that hypogammaglobuline-
mia could be attributed to the prior cyclophosphamide/steroid
exposure rather than to the cumulative rituximab dose. Finally,
the risk of hypogammaglobulinemia and infections seems to be
related to the underlying autoimmune condition: in patients with
rheumatoid arthritis or immune thrombocytopenia, the treat-
ment is well-tolerated without significant risk of infections and
hypogammaglobulinemia (22, 45–47).
We suggest that Ig levels should be always checked before ritux-
imab administration and monitored for at least 6 months after the
last dose. A longer period of observation should be addressed in
patients presenting with low Ig levels prior to rituximab-therapy
or in those who show risk factors for prolonged/severe hypogam-
maglobulinemia. In any case prompted IgRT should be offered,
either e.v. or subcutaneous, to those patients who complain severe
or recurrent infection episodes and concomitant low Ig levels.
BONE MARROW TRANSPLANTATION
Allogeneic bone marrow transplantation (ASCT) is a well estab-
lished therapy in hematological malignancies. Immune defects
are common consequences, persisting for years after ASCT. Arai
et al. (48) recently described that the cumulative incidence of
hypogammaglobulinemia (IgG< 400 mg/dl) in a cohort of 278
patients was 24.1 or 27.1%, respectively 1 or 3 years after ASCT.
Risk factors were lymphoid malignancies, history of previous
ASCT, usage of mycophenolate mofetil, low pre-ASCT IgG lev-
els, and grade 2–4 aGVHD. Norlin et al. (49) described that
patients with low IgG levels (<400 mg/dl) had an increased risk
of transplant-related mortality compared to patients with mod-
erately low or normal levels. Patients with low IgG levels had an
increased incidence of infections as cause of death.
A recent meta-analysis (6) summarizes data on IgRT in
patients undergone ASCT. When polyvalent Ig or hyperimmune
cytomegalovirus CMV-IVIG are compared, there are no dif-
ferences in mortality, rate of infections, CMV infections, and
microbiologically documented infections. Polyvalent Ig signifi-
cantly reduced the risk for interstitial pneumonitis but increased
the risk for veno-occlusive disease and adverse events. Moreover,
guidelines for preventing infectious complications provided by the
American Society of Bone Marrow Transplantation (50) suggest
that benefit is small if IVIG are used for prophylaxis of bacte-
rial infections in patients with severe hypogammaglobulinemia
(defined by authors as IgG< 400 mg/dL). The panel of experts rec-
ommends that IVIG dose and frequency should be individualized
to maintain trough serum IgG concentrations>400 mg/dL. Again,
IVIG are not recommended for CMV-disease prophylaxis after
ASCT. Interestingly, Sundin et al. (51) showed that SCIG therapy
is as effective as IVIG in maintaining IgG levels above 400 mg/dl
in pediatric patients after ASCT, and SCIG were associated to less
adverse events compared to IVIG.
SOLID ORGAN TRANSPLANTATION
Hypogammaglobulinemia has been reported as a complication
of solid organ transplantation, particularly after heart, lung, and
kidney transplantation, with an associated increased risk for infec-
tions. Moderate to severe hypogammaglobulinemia in recipients
of lung transplantation has been associated with increased occur-
rence of infections, longer hospitalization, and acute cellular rejec-
tion. Hypogammaglobulinemia appeared to be related to 1-year
all cause mortality. A recent meta-analysis by Florescu et al. (52)
found a consistent prevalence of hypogammaglobulinemia (45%)
and severe hypogammaglobulinemia (15%) during the first post-
transplant year. The risk of infections was higher (2.46-fold) when
IgG were less than 400 mg/dL; the risk of infections in patients
with IgG> 400 mg/dL did not differ with respect to patients with
normal Ig levels. This risk is related to the immune-suppressive
treatment, being particularly high if mycophenolate mofetil is
employed.
Concerning the role of IgRT in transplanted patients with
hypogammaglobulinemia it has been reported that IgRT favors
the reduction of infections rate (53, 54). Moreover, a single center
experience (55) suggested that SCIG replacement therapy repre-
sents a well-tolerated alternative to IVIG after lung transplanta-
tion. Unfortunately, these studies are heterogeneous in terms of
study populations or/and criteria of inclusion/exclusion for the
beginning of IgRT and definitive conclusion cannot be drawn.
Anyway, we suggest to start IgRT in patients with severe hypogam-
maglobulinemia, or in patients who complain recurrent infec-
tions reasonably related to low IgG levels. The proposed starting
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regimen should be 400 mg/kg of IVIG administered every 4 weeks,
subsequently adjusted to reach an individualized “biological”
trough level.
OTHER CAUSES OF SECONDARY
HYPOGAMMAGLOBULINEMIA
Conditions that frequently cause Ig loss include burns, renal, or
intestinal diseases. Protein-losing enteropathy is characterized by
an excessive loss of proteins into the gastrointestinal tract, result-
ing in some cases in symptomatic hypogammaglobulinemia. An
hypoproteinemic state with hypogammaglobulinemia can be also
a consequence of severe burns. Treatment of these disorders con-
sists mainly in the management of the underlying disease, and no
extensive data are available regarding IgRT.
A variety of infections has been recognized as an important
cause of morbidity and mortality in patients with nephrotic
syndrome. Immune defects in these patients are due to edema
complications, urinary loss of complement factors and Ig, and
defects in cellular immunity and secondary effects of immunosup-
pressive therapy. Many different prophylactic interventions have
been used for reducing the risks of infection in these patients but
recommendations for routine use are still lacking (56).
Hypogammaglobulinemia is present in a small percentage of
patients with thymoma (Good’s syndrome), usually symptomatic.
Often, hypogammaglobulinemia persists after the treatment of the
underlying disease. There are some reports on the efficacy of IgRT
in these patients (57, 58).
HIV INFECTION
HIV infection is peculiar in its immunological profile. Patients
usually exhibited hypergammaglobulinemia that encompassed all
three Ig classes, but given the T cell defect they failed to mount
specific antibody responses to various T cell dependent antigens,
and in particular encapsulated bacteria (59). In adults with HIV,
opportunistic infections are the most common manifestations of
the immune deficiency; instead, children frequently experience a
different immunological impairment, complaining of recurrent
serious bacterial infections (bacteremia and pneumonia) (60).
On the basis of the results obtained in the NICHHD trials
in 1991 (61) and several smaller studies previously performed,
IVIG have been approved for preventing invasive bacterial infec-
tions in children with HIV infection (400 mg/kg every 2–4 weeks).
IVIG seems to have only limited therapeutic benefit in terms of
mortality reduction in the acute phase of the bacterial infections
(60). The utility of IgRT has been later questioned, because antibi-
otic prophylaxis and especially retroviral therapy have dramatically
changed the clinical course of the disease (60); nowadays IgRT is
taken into account only in selective cases with recurrent bacterial
infections despite antiretroviral and antibiotic therapy.
Adult patients with HIV may retain their full complement
of B cells, and are less susceptible to infections with common
pathogens, even if HIV can profoundly affect humoral immunity
in a subset of patients. Several uncontrolled trials did not shown
conclusive benefits to routine IgRT (59). These studies should not
exclude the use of IVIG for adults who are infected with HIV-1 with
recurrent bacterial infections despite antiretroviral and antibiotic
therapy.
SUBCUTANEOUS IMMUNOGLOBULINS
Subcutaneous Ig have been widely shown to be safe, cost-effective,
and greatly appreciated in terms of Health-Related Quality of
Life (HRQL) in patients with PID (62–66). SCIG can be self
administered at home, do not require venous access and systemic
premedication, are characterized by a gradual absorption of the
drug and by a decrease in the incidence of systemic adverse effects
(66, 67). Local reactions are usually mild and do not affect the
good tolerability of the treatment (68).
Safety and efficacy of SCIG in SAD have been assessed in
few case series. We showed that SCIG are safe and effective in
maintaining adequate levels of serum IgG in patients with lym-
phoproliferative diseases (LPDs) and hypogammaglobulinemia
(9). We also observed an improvement perceived in HRQL. Simi-
lar results in term of efficacy, safety, and HRQL were obtained in
children after hematopoietic stem cell transplantation (51) and in
patients after lung transplantation (55).
Other potential benefits of SCIG should be considered in
patients with hematological malignancies. Venous access often
represents a great concern after chemotherapy treatments, and
SCIG provide the possibility to avoid the use of venous accesses.
The flexibility of SCIG treatment and the possibility of a home-
based infusion represent a further advance for patients who usually
need an high number of outpatient visits.
OPEN QUESTIONS
In this review, evidence has been provided suggesting that IgRT is
effective in most patients with SAD. Nonetheless, cost-effectiveness
advantage of initiating an IgRT in subjects with SAD has been
criticized by some authors. To provide a conclusive reply to this
criticism, a question should be definitively answered by future
studies: what criteria should be used to identify patients in
whom prophylactic IgRT may help to decrease infectious risk?
At present IgG levels represent the only parameter employed to
this aim. A better selection of patients in which IgRT is needed
can lead us to limit the perhaps too extended use of IgRT
in SAD.
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